{"filings":[{"id":1027280,"accession_number":"0001193125-26-269383","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2026-06-12T20:05:29+00:00","items":["5.07"],"status":"ready","headline":"Immunome shareholders elect three Class III directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["James Boylan elected with 70.2M votes for, 22.2M withheld; Sandra Swain and Philip Wagenheim each received over 92M votes for.","Ernst & Young ratified as independent auditor for FY 2026 with 104.1M votes for, 27,134 against.","Advisory vote on executive compensation approved: 90.9M for, 1.4M against, 31K abstentions.","Stockholders preferred annual advisory votes on exec compensation (91.9M for 1-year); company will hold annual votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40256,"accession_number":"0001193125-26-219367","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2026-05-12T20:05:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome Q1 2026 net loss $53.8M; NDA filed for varegacestat; cash $582.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $53.8M; R&D expenses $46.4M (incl. $3.7M stock comp); G&A $13.0M (incl. $4.2M stock comp).","Cash and equivalents $582.7M at March 31, 2026; expected to fund operations into 2028.","NDA submitted to FDA in April 2026 for varegacestat for desmoid tumors; Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026.","Phase 1 trial of IM-1021 ongoing with objective responses in B-cell lymphoma; initial lymphoma data expected in 2026.","IND clearance for IM-1617 (first-in-class ADC) in April 2026; INDs for IM-1340 and IM-1335 planned mid/late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104319,"accession_number":"0001193125-26-088141","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome reports FY2025 net loss $212.4M; cash $653.5M; varegacestat NDA planned Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $653.5M as of Dec 31, 2025; runway expected into 2028.","Net loss of $212.4M for FY2025; R&D expenses $177.3M.","Phase 3 RINGSIDE met primary endpoint: 84% reduction in risk of progression or death (HR=0.16, p<0.0001).","NDA submission for varegacestat in desmoid tumors planned for Q2 2026.","Three IND submissions for solid tumor ADCs (IM-1617, IM-1340, IM-1335) planned in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120615,"accession_number":"0001193125-25-322877","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunome prices $400M public offering of 18.6M shares at $21.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 18,625,000 shares at $21.50/share; gross proceeds ~$400M.","Underwriters granted 30-day option for up to 2,793,750 additional shares at same price.","Offering expected to close December 18, 2025; joint bookrunners include Leerink, J.P. Morgan, TD Cowen, Goldman Sachs, Guggenheim.","All shares sold by Immunome; proceeds before underwriting discounts and expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120614,"accession_number":"0001193125-25-318429","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Immunome Phase 3 RINGSIDE trial of varegacestat meets primary endpoint with 84% risk reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Progression-free survival HR=0.16 (95% CI 0.071-0.375, p<0.0001) vs placebo in desmoid tumors.","Confirmed ORR 56% with varegacestat vs 9% with placebo (p<0.0001); median tumor volume change -83% vs +11%.","All key secondary endpoints met; safety consistent with GSI class (most common AEs: diarrhea 82%, fatigue 44%, rash 43%).","NDA submission to FDA planned for Q2 2026; additional data to be presented at upcoming medical conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120613,"accession_number":"0001193125-25-269538","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome Q3 net loss $57.5M; cash $272.6M; varegacestat data due by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $57.5M for Q3 2025; cash and equivalents $272.6M.","Expects topline data from Phase 3 RINGSIDE (varegacestat) before end of 2025.","IM-1021 shows objective responses in B-cell lymphoma; initial data in 2026.","HC74 payload overcomes multi-drug resistance in preclinical models.","Cash runway into 2027; three preclinical ADCs targeting 2026 IND submissions."],"consensus_eps_estimate":-0.5857,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":6941000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137214,"accession_number":"0000950170-25-104015","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome Q2 net loss $43.4M; cash $268M; varegacestat Phase 3 topline data by end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.4M for Q2 2025; cash, equivalents and securities $268M as of June 30.","R&D expenses $40.5M, G&A $10.0M; cash expected to fund operations into 2027.","Varegacestat Phase 3 RINGSIDE Part B topline data expected before end of 2025; EMA granted Orphan Drug Designation in July 2025.","IM-1021 Phase 1 trial dosing at third dose level; IM-3050 IND cleared April 2025, Phase 1 start expected by end 2025.","Three preclinical ADCs (IM-1617, IM-1340, IM-1335) undergoing IND-enabling work; additional undisclosed ADCs in discovery."],"consensus_eps_estimate":-0.5395,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":6941000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154505,"accession_number":"0001104659-25-058523","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunome stockholders elect Barchas and Bienaimé as Class II directors; ratify Ernst & Young","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Isaac Barchas elected with 46.3M votes for, 15.2M withheld; Jean-Jacques Bienaimé elected with 47.1M for, 14.4M withheld.","Stockholders ratified Ernst & Young as auditor for FY2025 with 76.3M votes for, 16K against.","Broker non-votes totaled 14.7M on both director proposals; none on auditor ratification.","Meeting held June 10, 2025; 87,011,822 shares outstanding and entitled to vote as of April 21 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154504,"accession_number":"0001104659-25-047304","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunome Q1 net loss $41.6M; cash $317.3M; varegacestat data expected H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.6M for Q1 2025; R&D expense $36.9M, G&A $10.7M.","Cash, equivalents and marketable securities $317.3M as of March 31, 2025; expected to fund operations into 2027.","Phase 3 RINGSIDE trial of varegacestat fully enrolled; topline data expected in second half of 2025.","Phase 1 for IM-1021 (ROR1 ADC) ongoing; IM-3050 (FAP radiotherapy) IND cleared, trial to start H2 2025.","Amended 2024 Inducement Plan to increase reserved shares from 2M to 3.5M for new-hire equity grants."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":2926000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173054,"accession_number":"0001104659-25-025558","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome reports FY 2024 net loss of $293M; cash runway into 2027, pipeline milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $293.0M for FY 2024; cash & equivalents $217.3M at Dec 31, 2024.","January 2025 upsized offering raised $172.5M gross; cash runway now extends into 2027.","Phase 3 RINGSIDE topline data for varegacestat in desmoid tumors expected H2 2025.","Phase 1 of IM-1021 (ROR1 ADC) dosed first patient Feb 2025; IND for IM-3050 (FAP radioligand) submitted March 2025.","Preclinical ADCs IM-1617, IM-1340, IM-1335 in IND-enabling work; additional discovery programs ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173053,"accession_number":"0001104659-25-007610","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunome prices upsized $150M public offering of common stock at $7.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["19,354,839 shares priced at $7.75 per share; gross proceeds $150M.","Underwriters granted 30-day option to buy up to 2,903,225 additional shares.","Offering expected to close Jan 31, 2025, subject to customary closing conditions.","Joint book-running managers: J.P. Morgan, TD Cowen, Leerink Partners, Guggenheim Securities.","Offering upsized from initially announced $125M; all shares sold by Immunome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173052,"accession_number":"0001104659-25-007198","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Immunome launches public offering of common stock; pipeline update with Phase 3 data H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of common stock commenced; size not disclosed.","Preliminary cash, equivalents and marketable securities $217.3M as of Dec 31, 2024.","Varegacestat Phase 3 desmoid tumor trial fully enrolled; topline data expected H2 2025.","IM-1021 (ROR1 ADC) IND cleared Dec 2024; Phase 1 starts Q1 2025 at 2 mg/kg starting dose.","IM-3050 (FAP RLT) IND submission expected Q1 2025; three ADCs in IND-enabling manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173051,"accession_number":"0001104659-25-005594","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Max Rosett receives relocation package with $100K bonus and $300K housing bonus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$100,000 one-time cash relocation bonus paid within 10 days if relocation to Bothell, WA completed by Jan 21, 2026.","$300,000 housing bonus upon signing agreement to purchase primary residence near Bothell, subject to three-year pro-rata repayment.","Repayment obligations waived if CFO resigns for good reason or is terminated without cause.","Package incentivizes CFO to relocate and remain with Immunome long-term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190086,"accession_number":"0001104659-24-117682","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome Q3 net loss $47.1M, cash $240.1M; AL102 topline data H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $47.1M for Q3 2024; cash, equivalents and marketable securities $240.1M as of Sept 30, 2024.","R&D expenses $37.2M; in-process R&D $6.7M (related to business development); G&A $9.5M.","Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected H2 2025.","IND submissions for IM-1021 and IM-3050 on track for Q1 2025.","Cash runway expected to extend into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":6303000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190085,"accession_number":"0001104659-24-112053","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["1.01","1.02","2.01","3.02","9.01"],"status":"ready","headline":"Immunome acquires full ownership of ROR1 ADC assets from Zentalis for 1.8M shares plus $5M milestone","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued 1,805,502 shares of common stock to Zentalis as partial consideration for the asset purchase.","Obligated to pay $5M cash upon achievement of a developmental milestone; prior License Agreement terminated.","Standstill restrictions on Zentalis for one year; lockup on selling >50% of shares for six months.","Immunome to file resale registration statement within 30 days for shares issued to Zentalis.","Asset purchase includes ROR1 antibody-drug conjugate platform and related intellectual property."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190084,"accession_number":"0001104659-24-106777","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunome adopts 2024 Inducement Plan reserving 2M shares for new-hire equity grants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan reserves 2,000,000 shares of common stock for inducement awards to new employees.","Approved by Compensation Committee per Nasdaq Rule 5635(c)(4); no stockholder vote required.","Terms are substantially similar to the existing 2020 Equity Incentive Plan.","Awards limited to individuals not previously employed or returning after a bona fide non-employment period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206578,"accession_number":"0001104659-24-088340","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome reports Q2 2024 net loss of $36.1M; cash $278.4M, runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities totaled $278.4M; expected runway into 2026.","Net loss of $36.1M for Q2 2024; R&D expense $29.1M, G&A $7.0M.","Phase 3 RINGSIDE Part B (AL102) for desmoid tumors fully enrolled; topline data expected H2 2025.","IND submissions for IM-1021 and IM-3050 anticipated in Q1 2025.","Business development transactions with Atreca, Nectin Therapeutics, Bluefin, OncoResponse expanding ADC toolbox."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":3393000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223760,"accession_number":"0001104659-24-071253","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunome stockholders elect Siegall and Schafer as Class I directors; E&Y ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Clay B. Siegall elected with 43,295,914 votes for, 80,139 withheld; broker non-votes 6,682,195.","Carol A. Schafer elected with 33,452,580 votes for, 9,923,473 withheld; broker non-votes 6,682,195.","Ratification of Ernst & Young as auditor for FY2024: 50,008,641 for, 29,664 against, 19,943 abstain; no broker non-votes.","Annual Meeting held June 12, 2024; 59,943,368 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223759,"accession_number":"0001104659-24-060893","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome reports Q1 net loss $129.5M; cash $309.7M extends into 2026; AL102 topline data H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $129.5M ($2.51 diluted EPS) includes $112.0M in IPR&D expenses from AL101/AL102 and IM-1021 acquisitions.","Cash, cash equivalents and marketable securities $309.7M as of March 31, 2024; runway expected into 2026.","R&D expense $15.4M; G&A expense $6.0M, including $1.8M stock-based compensation.","Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected second half 2025.","IND submissions for IM-1021 (ROR1 ADC) and IM-3050 (FAP-targeted RLT) expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1029000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223758,"accession_number":"0001104659-24-054910","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunome VP Finance/PAO Bob Lapetina resigns; Max Rosett named PAO effective May 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bob Lapetina resigned as VP Finance, Corporate Controller and principal accounting officer effective May 10, 2024; departure not due to disagreement.","Max Rosett appointed principal accounting officer effective May 10, 2024; he currently serves as Interim CFO, EVP Operations since December 2023.","Rosett previously held roles at Morphimmune and Research Bridge Partners; no new material plan or contract entered in connection with appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223757,"accession_number":"0001104659-24-051944","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunome appoints Dr. Sandra Swain as Class III director, joins Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective April 25, 2024; term expires at 2026 annual meeting.","Annual cash retainer: $40,000 for Board, $7,500 for Audit Committee membership.","Initial option grant of $270,000 Black-Scholes value, vesting quarterly over three years.","Isaac Barchas stepped down from Audit Committee; new members: Schafer (Chair), Swain, Bienaimé.","Dr. Swain also receives automatic annual option grants of $135,000 vesting over 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243168,"accession_number":"0001104659-24-040503","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome posts FY2023 net loss of $106.8M; cash $138.1M, AL102 Phase 3 data due Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $106.8M ($5.38 per share) for FY2023; cash and equivalents $138.1M as of Dec 31, 2023 (prior to Feb 2024 $230M offering).","AL102 Phase 3 RINGSIDE topline data expected Q1 2025; IND filings for IM-1021 and IM-3050 expected Q1 2025.","Closed acquisition of AL102 from Ayala (Mar 2024) and licensed IM-1021 from Zentalis (Jan 2024).","Completed $230M underwritten offering in Feb 2024, extending cash runway into 2026.","R&D expenses $23.1M, IPR&D $80.8M, G&A $19.7M for FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243167,"accession_number":"0001104659-24-038744","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.01","1.01","3.02","7.01","9.01"],"status":"ready","headline":"Immunome completes acquisition of Ayala's AL102 Phase 3 desmoid tumor asset for $20M cash + stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of AL102 (Phase 3 gamma secretase inhibitor) and AL101; upfront $20M cash and 2,175,489 shares to Ayala.","Potential milestone payments up to $37.5M upon development and commercial milestones.","BMS license assumed: up to $142M clinical/regulatory milestones + $50M commercial milestones per product; royalties high single to low teen % on net sales.","CEO states AL102 may establish new standard of care for desmoid tumors; preclinical programs advancing to Phase 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243166,"accession_number":"0001104659-24-023641","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunome prices $200M follow-on offering of 10M shares at $20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 10,000,000 common shares at $20.00 each; gross proceeds ~$200M before expenses.","Underwriters have 30-day option to purchase up to 1,500,000 additional shares.","Closing expected February 16, 2024, subject to customary conditions.","Proceeds intended for general corporate purposes; J.P. Morgan, Cowen, Leerink, Guggenheim lead offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243165,"accession_number":"0001104659-24-019883","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Immunome announces $138.1M cash estimate, commences public offering; updates pipeline and AL102 acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and marketable securities of ~$138.1M as of Dec 31, 2023, subject to final close.","Underwritten public offering of common stock commenced; proceeds intended to fund pipeline and operations.","Signed asset purchase agreement with Ayala for AL102 (GSI) in desmoid tumors; expected close in late Q1 or early Q2 2024.","Pipeline: IND filings for IM-1021 (ROR1 ADC), IM-4320 (anti-IL-38), and FAP RLT all targeted for Q1 2025.","CEO Clay Siegall (former Seagen CEO) leads; management team includes former Morphimmune executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243164,"accession_number":"0001104659-24-010945","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Immunome to acquire AL102 Phase 3 desmoid tumor asset from Ayala for $20M cash + $30M stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Immunome will acquire AL102 and AL101 from Ayala for $20M cash and ~$30M in stock (2.18M shares).","Up to $37.5M in development and commercial milestone payments; closing requires Ayala stockholder approval.","AL102 is a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; Phase 2 data showed 75% ORR.","AL102 granted FDA Orphan Drug Designation in Nov 2023; desmoid tumors affect ~1,650 diagnosed annually in U.S.","Transaction to complement Immunome's targeted cancer pipeline; Ayala's stock trades OTCQX under ADXS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243163,"accession_number":"0001104659-24-009012","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunome promotes Max Rosett to EVP, Operations and Interim CFO; grants option for 175k shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Max Rosett promoted from SVP, Operations and Interim CFO to EVP, Operations and Interim CFO effective Jan 31, 2024.","Annual base salary increased to $425,000.","Granted option to purchase 175,000 shares at $16.57 per share (closing price on grant date).","Option vests 25% on one-year anniversary, then 36 equal monthly installments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243162,"accession_number":"0001104659-24-003380","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunome plans three INDs by 1Q 2025; closes Zentalis ADC license, Atreca antibody purchase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zentalis ADC license: $35M upfront (cash+stock), $275M milestones, mid-to-high single digit royalties for ROR1 ADC IM-1021.","Atreca antibody purchase: $5.5M cash upfront, $7M milestones for over 25 preclinical antibodies; closing subject to shareholder approval.","IND filings planned for 1Q 2025 for FAP radioligand therapy, ROR1 ADC (IM-1021), and IL-38 immunotherapy.","AbbVie collaboration: $30M upfront, up to $70M platform payments, $120M per target milestones, $150M per target sales milestones.","Preclinical data shows IM-1021 superior to MK-2140 in TNBC model; proprietary payload outperforms Enhertu in HER2-low model."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243161,"accession_number":"0001104659-24-002059","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Immunome licenses Zentalis' ROR1 ADC ZPC-21 and ADC platform for $35M upfront, up to $275M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive worldwide license for preclinical ROR1 ADC ZPC-21; IND submission targeted for 1Q 2025.","Upfront consideration: $35M in cash and Immunome common stock (2,298,586 shares).","Zentalis eligible for up to $275M in milestone payments plus mid-to-high single-digit royalties.","Immunome gains Zentalis' proprietary ADC platform technology for additional programs.","Zentalis agrees to standstill restrictions and share transfer limitations for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243160,"accession_number":"0001104659-24-000121","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunome appoints Carol Schafer as director, Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carol Schafer appointed Class I director, Chair of Audit Committee, and member of Nominating Committee, effective Jan 2, 2024.","Annual retainers: $40,000 for board, $15,000 for Audit Chair, $5,000 for Nominating Committee; plus option grant worth $270,000.","James Boylan and Jean-Jacques Bienaimé stepped down from Audit and Nominating Committees, respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260555,"accession_number":"0001104659-23-130516","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Immunome CFO Corleen Roche departs; Max Rosett named Interim CFO; Bob Lapetina named principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Corleen Roche separates effective Jan 2, 2024; receives 10.5 months salary continuation, $75,000 cash, COBRA coverage, and one-year option exercise extension.","Roche to provide consulting from Jan 2 to Apr 5, 2024 at $300/hour; equity continues vesting during consulting period.","Max Rosett appointed Interim CFO and principal financial officer; he has served as SVP Operations since Oct 2023.","Bob Lapetina appointed principal accounting officer; is VP Finance & Corp Controller since May 2021; eligible for two $15,000 retention bonuses through 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260554,"accession_number":"0001104659-23-129007","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immunome to acquire Atreca antibody assets for $5.5M upfront plus up to $7M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $5.5 million; additional $7.0 million in clinical development milestones.","Assets include certain antibody-related assets and materials from Atreca, Inc.","Transaction subject to customary conditions and Atreca stockholder approval.","Immunome expects to expand its pipeline with the acquired assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260549,"accession_number":"0001104659-23-120731","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K/A","filed_at":"2023-11-22T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Immunome files Morphimmune historical financials: 2022 net loss $7.5M, cash $7.2M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Morphimmune 2022 net loss of $7.5M (2021: $2.8M); accumulated deficit $11.2M as of Dec 31, 2022.","As of Dec 31, 2022, cash $7.2M, total assets $7.3M, total liabilities $0.8M.","R&D expense $4.2M in 2022 (2021: $0.5M); G&A $3.3M (2021: $1.6M).","Merger closed Sep 29, 2023; pro forma combined financials filed as Exhibit 99.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260553,"accession_number":"0001104659-23-118368","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Immunome presents pipeline update; cash runway into Q1 2026; 177Lu-FAP IND planned 1Q25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash runway expected into Q1 2026; recently completed $125M PIPE with leading healthcare investors.","Lead programs: first-in-class anti-IL-38 mAb and FAP-targeted radioligand therapy (177Lu-FAP).","IND filing for 177Lu-FAP anticipated in Q1 2025; preclinical data show single-dose antitumor activity.","Pipeline includes ADC strategy centered on novel targets; 70 antibody-target pairs identified to date.","Management team led by former Seagen CEO Clay Siegall; headquarters in Bothell, WA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260552,"accession_number":"0001104659-23-116348","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome completes Morphimmune merger, $125M PIPE, Q3 net loss $4M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed merger with Morphimmune; concurrent $125M oversubscribed PIPE from Enavate Sciences, EcoR1 Capital, Redmile, Janus Henderson, Avidity, Woodline.","Clay B. Siegall (ex-Seagen CEO) appointed Chairman & CEO; Bob Lechleider as CMO; Jean-Jacques Bienaimé (ex-BioMarin CEO) to board.","Q3 collaboration revenue $4M from AbbVie; R&D and G&A each $4M; net loss $4M ($0.36 per share); cash $91M as of Sept 30.","Cash runway extended into Q1 2026; expect IMM-ONC-01 IND guidance Q1 2024; 177Lu-FAP IND submission Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260551,"accession_number":"0001104659-23-115534","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Immunome appoints Jean-Jacques Bienaimé as Class II director; initial option grant of $270K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Jacques Bienaimé appointed as Class II director effective Nov 7, 2023, term through 2025 annual meeting.","Appointed to Audit, Compensation, and Nominating & Corporate Governance Committees.","Receives annual cash retainers totaling $57,500 ($40K board, $7.5K audit, $5K each for comp and nominating).","Granted initial option with Black-Scholes value of $270K vesting quarterly over three years.","Eligible for automatic annual option grants of $135K at each annual meeting, vesting over 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260550,"accession_number":"0001104659-23-106592","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["2.01","1.01","3.02","5.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Immunome completes merger with Morphimmune, raises $125M PIPE, appoints Clay Siegall as CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Oct 2, 2023: Morphimmune stockholders received 0.3042 shares per share; 8.84M shares issued.","Concurrent PIPE financing of ~$125M at $5.75/share; PIPE investors own 50.7% of post-merger company.","Prior Immunome stockholders own ~28.6%, prior Morphimmune ~20.7%.","New board of five directors; Clay Siegall (ex-Seagen CEO) appointed CEO, President, Chairman.","Material license agreement with Purdue: upfront $200k, milestones up to $3.75M, low single-digit royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277853,"accession_number":"0001104659-23-102807","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Immunome discloses merger-related lawsuits and supplemental proxy disclosures","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Two securities lawsuits filed by purported stockholders challenging the merger: Weiss v. Immunome (Sept 7) and Thompson v. Immunome (Sept 8).","Eleven stockholder demands and one books-and-records demand received regarding disclosure adequacy in the merger proxy.","Immunome denies wrongdoing but issues supplemental disclosures to avoid litigation costs and potential disruption to the merger.","Disclosures include details on the Transaction Committee, background discussions, discounted cash flow analysis ranges, and Dr. Siegall's recruitment.","Exchange ratio implies Immunome stockholders would own ~55% of the combined company on a fully diluted basis before PIPE and option grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277852,"accession_number":"0001104659-23-089110","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome Q2 net loss $5.6M; merger with Morphimmune and $125M PIPE deal announced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $5.6M ($0.46 per share) on $4.3M AbbVie collaboration revenue; R&D $5.7M, G&A $4.2M.","Cash and cash equivalents $38.4M as of June 30, 2023.","Definitive merger agreement with Morphimmune to combine platforms, expected close by end of 2023.","Clay Siegall, ex-Seagen CEO, to serve as Chairman and CEO of combined company.","Concurrent $125M private placement from institutional investors to support 3 IND filings within 18 months post-close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":6627000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277851,"accession_number":"0001104659-23-078220","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunome posts updated investor presentation suggesting combination with Morphimmune; no deal terms disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["On July 5, 2023, Immunome filed Form 8-K announcing posting of an updated investor presentation on its website.","Presentation is titled 'Morphimmune and Immunome Combined Corporate Presentation,' indicating a potential transaction.","No financial details, merger agreement, or definitive terms are provided in the filing or available exhibit text.","Filing does not include any forward-looking guidance, revenue impact, or timeline for the proposed combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295852,"accession_number":"0001104659-23-076136","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Immunome merges with Morphimmune; Siegall new CEO; $125M PIPE at $5.75/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Morphimmune stockholders to own ~45% of combined company; Immunome stockholders ~55% on fully diluted basis.","Clay Siegall to become Chairman and CEO; board to include 2 from Morphimmune, 1 from Immunome, 4 independents.","PIPE financing of ~$125M at $5.75/share (or $5.91 for affiliates) from Enavate, EcoR1, Redmile.","Siegall employment agreement: $650K base, 50% bonus target, option for 2.14M shares at $5.91.","Closing conditions include S-4 effectiveness, Nasdaq listing, PIPE proceeds of $125M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295851,"accession_number":"0001104659-23-070864","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Immunome shareholders reject officer exculpation amendment at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors Richard A. Baron and Philip Wagenheim elected until 2026.","Proposal to amend certificate for officer exculpation failed: 3,528,592 for, 86,542 against, 4,115,553 broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2023 approved: 7,578,396 for, 153,921 against.","Annual meeting held on June 7, 2023; quorum of 7,735,458 shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295850,"accession_number":"0001104659-23-056320","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome reports Q1 2023 net loss of $4.3M; posts $2.4M collaboration revenue from AbbVie deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration revenue of $2.4M from AbbVie strategic deal for up to 10 novel antibody-target pairs.","Net loss of $4.3M for Q1 2023; R&D expenses $3.9M, G&A expenses $2.8M.","Cash and cash equivalents $44.4M as of March 31, 2023.","AbbVie deal includes $30M upfront, $70M platform milestones, and up to $120M per target in development/commercial milestones.","Formed Antibody-Drug Conjugate and T Cell Redirection Advisory Board in February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":2364000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316393,"accession_number":"0001104659-23-033086","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome reports Q4 2022 net loss $7.8M; announces AbbVie collaboration with $30M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.8M ($0.64 per share) for Q4 2022; full-year net loss $36.9M ($3.09 per share).","Cash and equivalents $20.3M as of Dec 31, 2022.","Entered strategic collaboration with AbbVie for up to 10 novel antibody-target pairs; $30M upfront plus up to $70M platform milestones.","Per target: up to $120M in development/commercial milestones, $150M in sales milestones, plus tiered royalties.","Seeking partner for COVID-19 antibody cocktail IMM-BCP-01 after Phase 1b cohort completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316392,"accession_number":"0001104659-23-007738","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunome posts corporate presentation on website for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Posted presentation dated January 2023 under Item 8.01 of Form 8-K.","Presentation may be used in meetings with investors, analysts, collaborators, vendors.","Presentation attached as Exhibit 99.1 and incorporated by reference into Item 8.01.","Report signed by President and CEO Purnanand D. Sarma on January 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316391,"accession_number":"0001104659-23-001705","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Immunome partners with AbbVie for up to 10 novel oncology targets; $30M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Immunome grants AbbVie options to purchase up to 10 novel antibody-target pairs from three tumor types.","Upfront payment of $30M; potential platform access payments up to $70M based on research continuations.","Development and first commercial sale milestones up to $120M per target; sales milestones and tiered royalties low single digits.","Research term at least 66 months; exclusive to AbbVie for selected tumor types during term.","Collaboration leverages Immunome's Discovery Engine; Immunome retains platform technology rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316390,"accession_number":"0001104659-23-001704","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Immunome (IMNM) completes first cohort in Phase 1b COVID-19 antibody study; seeks partner","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First cohort of Phase 1b study of IMM-BCP-01 (COVID-19 antibody cocktail) dosed with no significant treatment-related adverse events.","Company plans to seek a partner to continue the trial and further development of IMM-BCP-01.","Entered into a Letter Agreement with Whitehead Institute modifying payment obligations under a 2009 license agreement with a collaborator.","Corporate presentation dated January 2023 posted on company website for investor and partner meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334663,"accession_number":"0001104659-22-119142","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Immunome posts corporate presentation; details unavailable in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated November 15, 2022 posted to company website for investor meetings.","Slide title references 'Harnessing the Human Cell the Power of Memory B'.","No financial or pipeline updates visible in the provided exhibit excerpt.","Ticker IMNM; filing under Item 8.01 (other events) is a voluntary disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334662,"accession_number":"0001104659-22-117891","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Immunome reports Q3 net loss of $8.5M; cash $27.1M; COVID antibody trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2022 was $8.5 million; no revenue from product sales.","R&D expenses $5.2M, G&A $3.3M; cash and equivalents $27.1M as of Sept 30.","IMM-BCP-01 Phase 1b enrollment expected by end of 2022; topline data early 2023.","Oncology pipeline advancing; IND for IMM-ONC-01 planned by mid-2023.","Preclinical data on anti-EPN1 antibody IMM20059 at SITC showed combo effect with atezolizumab."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334661,"accession_number":"0001104659-22-106786","cik":1472012,"company_name":"Immunome Inc.","ticker":"IMNM","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Immunome terminates Deloitte as auditor, appoints Ernst & Young effective Oct 4, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee terminated Deloitte on Sept 30, 2022; appointed EY effective Oct 4, 2022.","Deloitte's audits for FY 2021 and 2020 contained no adverse opinion or qualification.","No disagreements on accounting principles or reportable events during FY 2021-2022 interim periods.","No prior consultations with EY regarding accounting principles or audit opinions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2552663840.6549067,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-06T23:59:59+00:00|334661"}